Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Next Previous
Trial Profile

A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP-1503 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Male breast cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Evelo Biosciences

Most Recent Events

  • 09 Dec 2020 According to an Evelo Biosciences media release, the company has decided to halt and wind down this study, as company has prioritizing EDP1908 as its lead clinical candidate in oncology given its superior preclinical activity over EDP1503.
  • 09 Dec 2020 According to an Evelo Biosciences media release, data from this study were presented at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting.
  • 09 Dec 2020 Results presented in an Evelo Biosciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top